Articles On Memphasys (ASX:MEM)

Title Source Codes Date
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead MEM 4 days ago
Closing Bell: Blood plasma giant CSL bleeds out in front of entire ASX on Monday

  ASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small cap winners led by American Rare Earths and Appen   The benchmark was shot through the heart by CSL this morning leaving everything else in...

Stockhead MEM 2 weeks ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead MEM 3 months ago
Closing Bell: Even the Aussie dollar appreciates a good lead as dynamic surge makes local IT the it sector for a day

ASX200 closes 0.9pc higher Property stocks and IT sector enjoy huge day Small caps led by DCL   The Australian sharemarket has lifted strongly on Day Two of Trading in November, the Best Month for Trading Ever. Local investors got stuck r...

Stockhead MEM 4 months ago
10 at 11ish: Magnum Mining inks Saudi deal, Novonix scores US$100m grant

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

Stockhead MEM 4 months ago
Memphasys to reinvest tax refund in the next generation

Australian biotechnology company, Memphasys says a $1.3 million research and development tax refund from the ATO will repay a loan and interest, while the net refund will be reinvested as working capital.

The West MEM 4 months ago
Memphasys to reinvest tax refund in the next generation

Australian biotechnology company, Memphasys says a $1.3 million research and development tax refund from the ATO will repay a loan and interest, while the net refund will be reinvested as working capital.

The West MEM 4 months ago
Closing Bell: It certainly wasn’t cricket as Monday markets in Australia knocked right back to last year

Benchmark ASX index closes at new 12-month lows Energy and Materials the worst of 9 dipping ASX sectors on Monday Small caps led by CHM, TON   On Monday Aussie markets rediscovered their nadir of the year. No real surprises, since every n...

Stockhead MEM 4 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead MEM 4 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead MEM 5 months ago
Memphasys brings Indian baby dreams alive with Felix

Just when all looked lost for a group of parent hopefuls in India, a piece of Australian medical technology developed by Memphasys has turned their dreams of the pitter-patter of tiny feet into reality.

The West MEM 5 months ago
Memphasys brings Indian baby dreams alive with Felix

Just when all looked lost for a group of parent hopefuls in India, a piece of Australian medical technology developed by Memphasys has turned their dreams of the pitter-patter of tiny feet into reality.

The West MEM 5 months ago
TMH Market Update: Woodside (ASX:WDS) stalls seismic testing at Scarborough gas project off WA

ASX200 is making a strong run into the weekend – up 1.5 per cent with all sectors ahead.  Seismic testing for Woodside’s (WDS) Scarborough gas project off Western Australia’s northern coast has stalled, despite approvals attained in July...

themarketherald.com.au MEM 5 months ago
Memphasys’ (ASX:MEM) FELIX system records 10 new healthy births in India

Memphasys’s (MEM) FELIX sperm separation technology has led to 11 successful pregnancies and births in India with 10 more announced today The company’s FELIX product is a compact box device box that separates the largest sperm from seme...

themarketherald.com.au MEM 5 months ago
ASX Health Stocks: Memphasys reports 10 new live births in India using its Felix System

Memphasys reported 10 new live births in India using its Felix system Ramsay Health Care’s credit rating downgraded by Fitch   Memphasys reports 10 new live births in India Reproductive-focused biotech Memphasys (ASX:MEM) has just reporte...

Stockhead MEM 5 months ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead MEM 5 months ago
Top 10 at 11: This morning’s early gains are brought to you by lithium, nickel and… almonds.

Stockhead’s Top 10 at shortly-before-11-ish, published shortly after I’ve located my reading glasses and wiped the bacon grease off my fingers at the start of each trading day. It highlights the best (and sometimes worst) performing ASX sto...

Stockhead MEM 5 months ago
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead MEM 6 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead MEM 6 months ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead MEM 6 months ago
CLOSING BELL: ASX eases to 0.39pc, led to greener pastures by a surging Health Care market

 The ASX 200 benchmark has climbed down from highs at lunch to finish on +0.39%. Health Care was well out in front of the market all day, thanks to a chunky bump for CSL. Voltaic Strategic Resources won the Small Caps Cup, rising 22.5% for...

Stockhead MEM 6 months ago
CLOSING BELL: Local markets dip 0.86pc on Chinese developer woes and other bad bets

ASX benchmark falls 0.86% for the day, dragged down by bad news from China. Telcos, Energy and InfoTech tried their best, but the overall gloom was too much to fight. Lithium Universe (ASX:LU7) banks a solid market debut as it kicks off i...

Stockhead MEM 6 months ago
Memphasys franks Japan deal with first Felix order

Just a week into its pivotal deal with global IVF provider Vitrolife, reproductive biotechnology company Memphasys has already received its first order to put its patented Felix system into clinics in Japan.

The West MEM 6 months ago
ASX Health Stocks: Firebrick achieves primary endpoint in Phase 2; Memphasys surges 20pc on Japan deal

Firebrick achieved primary endpoint in Phase 2 Memphasys rise 20pc after distribution deal in Japan Clarity Pharma says ‘pre-targeting’ presents groundbreaking avenue   Firebrick achieves primary endpoint in Phase 2 Firebrick Pharma (ASX:...

Stockhead MEM 6 months ago
Top 10 at 10: Lithium Australia hops into bed with big gun Mineral Resources

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead MEM 6 months ago
Market Highlights: Wall Street megacaps slip, China’s deflation, and best day to buy Bitcoin

The ASX will open lower on Monday Wall Street megacaps mainly fell on Friday This week’s focus will be on US CPI data   The ASX 200 is set to open lower on Monday and extend its 1% loss last week. At 8am AEST, the ASX 200 index futures wa...

Stockhead MEM 6 months ago
Memphasys inks deal with global IVF provider Vitrolife

Reproductive technology specialist Memphasys has inked an exclusive five-year distribution deal with Vitrolife – a global provider of human IVF medical devices – to sell its patented Felix system in Japan.

The West MEM 6 months ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead MEM 7 months ago
Memphasys locks in new patents for flagship IVF treatment

Reproductive biotechnology company Memphasys been granted two new Australian patents for its flagship Felix system, ensuring that the integrity of its IVF treatment device is protected in all markets.

The West MEM 7 months ago
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead MEM 8 months ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead MEM 8 months ago
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Stockhead MEM 9 months ago
CLOSING BELL: Someone please give the market a nudge… I think it’s fallen asleep

The ASX fell this morning and – sadly – just never recovered. It’s down 0.64%. Aside from Happy Times among the lithium players, it’s been a total snoozefest Rubix Resources (ASX:RB6) takes bragging rights with a 41.6% hike for the day  ...

Stockhead MEM 9 months ago
Closing Bell: Its another win for the ASX on Friday as Austral nabs US$3 billion US Navy deal

S&P/ASX 200 closes up 0.6%, while the emerging companies index rises 0.86% Austral’s US subsidiary Austral USA awarded a contract worth up to US$3.195 billion from the US Navy Pushpay ceases trading on the ASX and NZX following its $1....

Stockhead MEM 9 months ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead MEM 10 months ago
TMH Spotlight: Material stocks rise despite hit to sector

Despite the materials sector having a tough run today on the back of lower gold, silver and copper prices, many small- and mid-caps in this space are making headway. Dreadnought Resources (DRE) has defined a wide zone of rare earth eleme...

themarketherald.com.au MEM 11 months ago
Memphasys (ASX:MEM) welcomes first baby born in India using Felix system

Memphasys (MEM) reports the first live birth of a healthy baby boy in India using its Felix system at the Coimbatore Women’s Hospital Centre However, Memphasys has temporarily suspended sales of Felix into the country following changes...

themarketherald.com.au MEM 11 months ago
Market Highlights: ASX to rise again, oil prices spike 7pc, and 5 small caps to watch on Monday

Aussie shares to extend gains on Monday after a rally in New York EU inflation continues to be at record high Oil prices spiked 7pc as OPEC+ announced cuts   Aussie shares are set to open higher again on Monday, tracking stocks in New Yor...

Stockhead MEM 11 months ago
ASX Today: Stocks to watch on Monday

The ASX is expected to open the new week higher ahead of the much-anticipated RBA rates decision on Tuesday. ASX futures were also up over the weekend. Here are some ASX-listed companies to look out for during Monday’s trade: Dreadnou...

themarketherald.com.au MEM 11 months ago
Dr Boreham’s Crucible: Every sperm is sacred – and profitable

What’s wrong with our tadpoles, gentlemen? According to local fertility expert Prof John Aitken, sperm counts have roughly halved over the last 50 years and about 20 per cent of men shoot blanks. No-one’s sure why, but possible reasons incl...

Stockhead MEM 11 months ago
CLOSING BELL: Is a $1.2 billion dollar catastrophe enough to finally hammer a stake through the heart of Star?

The ASX extended the week’s losses by falling 0.4% today Star Entertainment Group posted a loss so large it almost defies description Mt Monger has had a fantastic day, up 46.6% after joining the Great Canadian REE Rush   The ASX has fall...

Stockhead MEM 1 year ago
The Week that Was: February 6-10, 2023

ShareCafeThe Week that Was: February 6-10, 2023 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so,...

ShareCafe MEM 1 year ago
Memphasys (ASX: MEM) Felix System Findings

ShareCafeMemphasys (ASX: MEM) Felix System Findings Memphasys (ASX: MEM) has announced the first publications of study findings by key opinion leaders of the Felix System. Memphasys (ASX: MEM) Felix System FindingsFinance News Network

ShareCafe MEM 1 year ago
ASX closes 0.46% lower after RBAs 25 basis point hike

ShareCafeASX closes 0.46% lower after RBAs 25 basis point hike by Peter Milios   The Reserve Bank of Australia has raised the official interest rate for the ninth consecutive time to 3.35 per cent. The bank indicated that more rate hikes ma...

ShareCafe MEM 1 year ago
Peer review confirms Memphasys’ Felix system superior to conventional sperm preparation for human IVF

This content is created by Smallcaps Authors. [Author : Imelda Cotton] In vitro results from study findings on the Felix system developed by reproductive biotechnology company Memphasys (ASX: MEM) have demonstrated it can outperform conve...

SmallCaps MEM 1 year ago
ASX Health Stocks: Creso eyes psychedelic spinout off the back of landmark TGA decision

Creso looks to potentially spin out psychedelic subsidiary  Two studies show Memphasys’ Felix reproductive tech outperforms WOA’s Dirty Clean Food brand nabs WHSmith retail deal   Yesterday the big news in the health sector was the Thera...

Stockhead MEM 1 year ago
ASX up 0.12% at noon as investors await this afternoon’s RBA meeting

ShareCafeASX up 0.12% at noon as investors await this afternoon’s RBA meeting by Peter Milios   Investors are cautious as they await the outcome of the Reserve Bank’s meeting and examine local earnings updates. As a result, the Australian s...

ShareCafe MEM 1 year ago
Stocks of the Hour: C29, EVR, MEM

ShareCafeStocks of the Hour: C29, EVR, MEM                    C29 Metals (ASX:C29) advises that drilling at their Pocitos 7 project in Argentina has concluded at 420 metres, with a packer test intercepting a deep aquifer from 370-400...

ShareCafe MEM 1 year ago
Stocks of the Hour: C29 Metals, EV Resources, Memphasys

07 Feb 2023 - A snapshot of the stocks on the move featuring C29 Metals (ASX:C29), EV Resources (ASX:EVR) and Memphasys (ASX:MEM).

FNN MEM 1 year ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead MEM 1 year ago